These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11909981)

  • 61. [Neuroprotective effect of dopamine agonists].
    Szczudlik A; Rudzińska M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S22-8. PubMed ID: 17941455
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 65. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.
    Joyce JN; Millan MJ
    Curr Opin Pharmacol; 2007 Feb; 7(1):100-5. PubMed ID: 17174156
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease.
    Jiang C; Wan X; Jankovic J; Christian ST; Pristupa ZB; Niznik HB; Sundsmo JS; Le W
    Clin Neuropharmacol; 2004; 27(2):63-73. PubMed ID: 15252266
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antiparkinsonian drugs and their neuroprotective effects.
    Kitamura Y; Kakimura J; Taniguchi T
    Biol Pharm Bull; 2002 Mar; 25(3):284-90. PubMed ID: 11913520
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neuroprotection in idiopathic Parkinson's disease.
    Reichmann H
    J Neurol; 2002 Oct; 249 Suppl 3():III/21-3. PubMed ID: 12522567
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
    Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Ahlskog JE
    Neurology; 2003 Feb; 60(3):381-9. PubMed ID: 12580184
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Etiopathogenesis and treatment of Parkinson's disease.
    Gallagher DA; Schapira AH
    Curr Top Med Chem; 2009; 9(10):860-8. PubMed ID: 19754402
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes].
    Szczudlik A; Rudzińska M
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S6-9. PubMed ID: 17941452
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
    Ogawa N
    Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.
    Shadfar S; Kim YG; Katila N; Neupane S; Ojha U; Bhurtel S; Srivastav S; Jeong GS; Park PH; Hong JT; Choi DY
    Mol Neurobiol; 2018 Jan; 55(1):554-566. PubMed ID: 27975170
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Minocycline: neuroprotective mechanisms in Parkinson's disease.
    Thomas M; Le WD
    Curr Pharm Des; 2004; 10(6):679-86. PubMed ID: 14965330
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease.
    Chen LW; Yung KK; Chan YS
    Curr Drug Targets; 2004 Feb; 5(2):197-206. PubMed ID: 15011953
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Dopaminergic neuroprotection and reconstruction of neural network tiara].
    Kitamura Y
    Yakugaku Zasshi; 2010 Oct; 130(10):1263-72. PubMed ID: 20930477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.